➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Baxter
Harvard Business School
AstraZeneca
Medtronic
Merck

Last Updated: August 5, 2020

DrugPatentWatch Database Preview

CARTIA XT Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Cartia Xt, and what generic alternatives are available?

Cartia Xt is a drug marketed by Actavis Labs Fl Inc and is included in one NDA.

The generic ingredient in CARTIA XT is diltiazem hydrochloride. There are twenty-six drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the diltiazem hydrochloride profile page.

Drug patent expirations by year for CARTIA XT
Drug Prices for CARTIA XT

See drug prices for CARTIA XT

Drug Sales Revenue Trends for CARTIA XT

See drug sales revenues for CARTIA XT

Recent Clinical Trials for CARTIA XT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
The University of Hong KongPhase 4

See all CARTIA XT clinical trials

Pharmacology for CARTIA XT

US Patents and Regulatory Information for CARTIA XT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Actavis Labs Fl Inc CARTIA XT diltiazem hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 074752-002 Jul 9, 1998 AB3 RX No No   Start Trial   Start Trial   Start Trial
Actavis Labs Fl Inc CARTIA XT diltiazem hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 074752-004 Jul 9, 1998 AB3 RX No No   Start Trial   Start Trial   Start Trial
Actavis Labs Fl Inc CARTIA XT diltiazem hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 074752-001 Jul 9, 1998 AB3 RX No No   Start Trial   Start Trial   Start Trial
Actavis Labs Fl Inc CARTIA XT diltiazem hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 074752-003 Jul 9, 1998 AB3 RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
McKinsey
Merck
Express Scripts
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.